Skip to main content
  • Poster presentation
  • Open access
  • Published:

Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis


To evaluate the clinical and functional activity of patients with rheumatoid arthritis at one and two years after starting anti-TNF therapy.

Patients and methods

This is a retrospective study of 50 RA patients, who started ANTI-TNF theraphy between June 2006 and july 2009. The main variables in the study were: DAS28, HAQ and pain VAS. We analyzed evolution after 1 year and 2 years from the beginning of the treatment. The comparison with the basal state was made with Student’s t test. The statistical study was analyzed by the SPSS 18,0.


The study includes 50 patients, 66% female, with RF in 76% and erosions in 64%, treated with etanercept (28), adalimumab (13) and infliximab (9). Most of them (70%) had recieved at least 2 FAMES before biological. In the below table we compare changes in clinical parameters for different biologics after one and two years.

Table 1


All anti-TNF significantly improve disease activity, functional status and pain VAS after the first year. This improvement continues but not significantly increases the second year.

Etanercept is the only drug with a significant reduction for HAQ, DAS28 and pain VAS.

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Martínez-Pérez, R., Uceda, J., León, M. et al. Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis. J Transl Med 9 (Suppl 2), P46 (2011).

Download citation

  • Published:

  • DOI: